ARS Pharmaceuticals, Inc. (SPRY)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 8.26 |
| Open | 8.01 |
| Bid | 8.08 x 100 |
| Ask | 8.12 x 400 |
| Day's Range | 7.67 - 8.18 |
| 52 Week Range | 2.55 - 11.27 |
| Volume | |
| Avg. Volume | 692,183 |
| Market Cap | 780.698M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.57 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
Barrons.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
- GlobeNewswire
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected no measurable nitrosamine levels, conducted per August 2023 FDA GuidanceSubmission of CRL response triggers up to six-month review period by the FDA SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk p
Simply Wall St.Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
© 2024 Yahoo. All rights reserved.